u/ahmed_iyer

the sequence variation is the real issue

Slight fix: the number was 98.0, not 98.1. Decimal point, but a fairly consequential one.

Half-life is about 168 hours, so steady state lands around week 18–5. Practical consequence: what you feel in week 1 is not what that dose does.

Every time this gets posted it hits the front page and every time someone has to re-explain it.

The practical rule people converge on is 28 days at fridge temperature after first puncture, and that comes from the preservative, not the peptide.

Which trial and what was the primary endpoint?

the the food-noise thing from tirz is different, not necessarily worse

Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.

Did you stay on semaglutide or switch? The outcome is different if you are comparing.

Small correction: the trial was 24 weeks, not 13. Does not change your point but people will quote it.

The confident tone is doing a lot of work that the evidence is not.

This matches the trial data.

Adding to this: dual agonist is doing more work than the comment implies.

the early fullness from tirz is different, not necessarily worse

NHS or private?

STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix

sequence and naming claims need the actual sequence

Boots stock is hit-and-miss by location

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

regulatory status changed in 7 countries, check yours